What adjustments, if any, do you make to chemotherapy regimens for patients with chromosomal breakage disorders who develop malignancy?
Are there particular drugs you avoid or dose-adjustments that are recommended?
1 Answer
Mednet MemberInvited Expert
Pediatric Hematology/Oncology · UPMC Children’s Hospital of Pittsburgh
Answered on
Patients with known DNA repair disorders (such as Ataxia-Telangiectasia, Nijmegen Breakage Syndrome) are at high risk of developing toxicity from standard chemotherapy approaches for the treatment of their leukemia/lymphoma, which is the most common malignancy they are predisposed to.
Join for free or sign in to see the full answer